Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I. Sherman

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
The Journal of Clinical Endocrinology and Metabolism|July 23, 2018
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineTania Jaber, Steven G Waguespack, Maria E Cabanillas, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatmentDavid L Schwartz, Mark J Lobo, K Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerGerald S Falchook, Michael Millward, David Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2017
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroidMakoto Tahara, Martin Schlumberger, Rossella Elisei, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
The Journal of Clinical Endocrinology and Metabolism|July 23, 2018
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineTania Jaber, Steven G Waguespack, Maria E Cabanillas, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatmentDavid L Schwartz, Mark J Lobo, K Kian Ang, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
The Oncologist|April 16, 2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerRamona Dadu, Steven G Waguespack, Steven I Sherman, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Thyroid : Official Journal of the American Thyroid Association|October 7, 2014
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerGerald S Falchook, Michael Millward, David Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2017
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroidMakoto Tahara, Martin Schlumberger, Rossella Elisei, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2014
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experienceRamona Dadu, Komal Shah, Naifa L Busaidy, et al.
Pageof 15